Using artificial intelligence tools in answering important clinical questions: The KEYNOTE-183 multiple myeloma experience.
Sign Up to like & getrecommendations! Published in 2020 at "Contemporary clinical trials"
DOI: 10.1016/j.cct.2020.106179
Abstract: The phase III, randomized, active-controlled, multicenter, open-label KEYNOTE-183 study (NCT02576977) evaluating pomalidomide and low dose dexamethasone (standard-of-care [SOC]) with or without pembrolizumab in patients with refractory or relapsed and refractory multiple myeloma (rrMM) was placed… read more here.
Keywords: using artificial; multiple myeloma; ecog performance; keynote 183 ... See more keywords
Abstract PO-029: Using treatment to determine ECOG performance status in metastatic pancreatic cancer
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Research"
DOI: 10.1158/1538-7445.panca20-po-029
Abstract: Aim: ECOG Performance status (PS) is a major prognostic factor in patients with metastatic pancreatic cancer (mPAC) and is one of key factors to consider in treatment selection. However, there is limited ability to determine… read more here.
Keywords: performance status; metastatic pancreatic; treatment; pancreatic cancer ... See more keywords